Impact of the PIK3CA mutation on breast cancer

Breast cancer was a health priority both globally and in Argentina, where it was the leading cause of death from tumours in women. Its molecular and genetic understanding has led to advances in diagnosis, prognosis and treatment. The luminal subtype, characterised by hormone receptors, and the PIK3CA gene mutation, involved in the PI3K/Akt/mTOR pathway, were highlighted as being associated with greater tumour aggressiveness and resistance to therapies. In Argentina, studies have shown a high prevalence of this mutation, prompting the use of targeted therapies such as Alpelisib. This personalised approach has improved the stratification and clinical management of the disease.